CDT Equity Inc.

Stage 4 · Declining · week 120

As of Oct 22, 2026, CDT Equity is in Stage 4, the downtrend phase, now in week 120 (since Jun 3, 2024). It closed at $0.13, 100.0% below its 52-week high and below its 200-day average, which is falling.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. More about the company

$0.13

-10.34% today

$146,299 · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CDT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 125w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 1w → S4 12w → S1 8w → S4 7w → S1 6w → S4 125w current

Total tracked: 165 weeks across 7 stage runs.

CDT among Biotechnology555th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…555	CDTCDT Equity Inc.	Stage 4 · wk 120	1	−96.1%

vs 52W High

-100.0%

$0.13 lo$19,375.00 hi

100.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 120

1w13w26w

Week 120, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-100.0%

200 DMA: $1,819.86 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.85x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-96.1%

-99.8%

-100.0%

YTD

-100.0%

Scan Membership

Breakout Watch

Latest: 2023-01-11

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 120 · Vol 1.85x

2026-10-21S4

Wk 120 · Vol 1.61x

2026-10-20S4

Wk 120 · Vol 1.86x

2026-10-19S4

Wk 120 · Vol 1.35x

2026-10-16S4

Wk 120 · Vol 15.48x

2026-10-15S4

Wk 119 · Vol 3.06x

2026-10-14S4

Wk 119 · Vol 80.95x

2026-10-13S4

Wk 119 · Vol 3.76x

2026-10-12S4

Wk 119 · Vol 1.46x

2026-10-09S4

Wk 119 · Vol 1.94x

2026-10-08S4

Wk 118 · Vol 1.12x

2026-10-07S4

Wk 118 · Vol 2.14x

Moving averages & range

50 DMA

$19.97

200 DMA

$1,819.86

52W High

$19,375.00

52W Low

$0.13

5D Low

$0.13

Resistance levels (recent highs)

20d High

$2.00

60d High

$89.75

120d High

$565.00

250d High

$19,250.00

Next resistance

+1438.5%

to 20d High

P/E (TTM)

0.0

Forward —

ROE

-69.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.0

CDT Equity: quick answers

What stage is CDT Equity in?

As of Oct 22, 2026, CDT Equity (CDT) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 3, 2024 and is in week 120. What the four stages mean

Is CDT Equity in an uptrend?

No. CDT Equity is in a Stage 4 downtrend. It trades 100.0% below its 200-day average, which is falling.

How far is CDT Equity from its 52-week high?

CDT Equity closed at $0.13 on Oct 22, 2026, 100.0% below its 52-week high of $19,375.00. Its 52-week low is $0.13.

How has CDT Equity performed over the past year?

As of Oct 22, 2026, CDT Equity is down 100.0% over the past year and down 100.0% so far in 2026.

Which sector and industry is CDT Equity in?

CDT Equity is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.